Join Growin Stock Community!

Teva pharmaceutical industries limitedTEVA.US Overview

US StockHealthcare
(No presentation for TEVA)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

TEVA AI Insights

TEVA Overall Performance

TEVA AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

TEVA Recent Performance

0.15%

Teva pharmaceutical industries limited

0.05%

Avg of Sector

-0.31%

S&P500

TEVA PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

TEVA Key Information

TEVA Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

TEVA Profile

Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.

Price of TEVA

TEVA FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

TEVA Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.23
PE Ratio (TTM)
27.98
Forward PE
13.67
PS Ratio (TTM)
2.29
PB Ratio
4.97
Price-to-FCF
33.74
METRIC
VALUE
vs. INDUSTRY
Gross Margin
51.79%
Net Margin
8.16%
Revenue Growth (YoY)
4.32%
Profit Growth (YoY)
10.84%
3-Year Revenue Growth
6.65%
3-Year Profit Growth
14.45%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
1.23
PE Ratio (TTM)
27.98
Forward PE
13.67
PS Ratio (TTM)
2.29
PB Ratio
4.97
Price-to-FCF
33.74
Gross Margin
51.79%
Net Margin
8.16%
Revenue Growth (YoY)
4.32%
Profit Growth (YoY)
10.84%
3-Year Revenue Growth
6.65%
3-Year Profit Growth
14.45%

  • When is TEVA's latest earnings report released?

    The most recent financial report for Teva pharmaceutical industries limited (TEVA) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating TEVA's short-term business performance and financial health. For the latest updates on TEVA's earnings releases, visit this page regularly.

  • Where does TEVA fall in the P/E River chart?

    According to historical valuation range analysis, Teva pharmaceutical industries limited (TEVA)'s current price-to-earnings (P/E) ratio is 29.56, placing it in the Reasonable zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of TEVA?

    According to the latest financial report, Teva pharmaceutical industries limited (TEVA) reported an Operating Profit of 303M with an Operating Margin of 6.43% this period, representing a growth of 1,542.86% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is TEVA's revenue growth?

    In the latest financial report, Teva pharmaceutical industries limited (TEVA) announced revenue of 4.71B, with a Year-Over-Year growth rate of 11.4%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much debt does TEVA have?

    As of the end of the reporting period, Teva pharmaceutical industries limited (TEVA) had total debt of 17.09B, with a debt ratio of 0.42. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.

  • How much cash does TEVA have?

    At the end of the period, Teva pharmaceutical industries limited (TEVA) held Total Cash and Cash Equivalents of 3.56B, accounting for 0.09 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does TEVA go with three margins increasing?

    In the latest report, Teva pharmaceutical industries limited (TEVA) achieved the “three margins increasing” benchmark, with a gross margin of 56.4%%, operating margin of 6.43%%, and net margin of 10.2%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess TEVA's profit trajectory and future growth potential.

  • Is TEVA's EPS continuing to grow?

    According to the past four quarterly reports, Teva pharmaceutical industries limited (TEVA)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 0.42. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of TEVA?

    Teva pharmaceutical industries limited (TEVA)'s Free Cash Flow (FCF) for the period is 1.02B, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 127.8% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.

  • What are the PEG ratio and PE ratio of TEVA?

    The latest valuation data shows Teva pharmaceutical industries limited (TEVA) has a Price-To-Earnings (PE) ratio of 29.56 and a Price/Earnings-To-Growth (PEG) ratio of 1.77. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.